AVH 4.39% $3.09 avita medical inc.

Don't consider selling before profitability, page-367

  1. 462 Posts.
    lightbulb Created with Sketch. 907
    Since the update that revenue for Q1 is expected to be 36% lower than previous guidance (at midpoints - $15.2M/$11.15M), the share price has dropped 36%.

    https://hotcopper.com.au/data/attachments/6107/6107627-528ee3b9c56b7bd0279767ec4cb6291a.jpg

    It could be argued that this is a 32% overreaction since FY24 guidance is expected to be 4% lower than the midpoint of previous guidance ($81.5M/$78.5M).

    However, in the absence of more reassuring explanations on the Q1 revenue downgrade and their confidence around FY24 revenue expectations, and an the increasing number of other misses - a proportion of investors are now doubting future guidance and questioning their investment, hence the rerate.

    I hope it turns out that we were too harsh, especially on dismissing FY24 revenue guidance, but history is suggesting otherwise. Unfortunately, we have to wait around a month before we get a clearer picture.

    I agree that the Avita team are best suited for the VAC process due to their product knowledge and motivation, and they will establish working relationships along the way. As I previously posted, the number of VAC approvals are ahead of my expectations. Investors and JC should know from burns, it can be a lengthy process, sometimes taking years to get approval. If people think it could be just a RECELL issue, keep in mind that PolyNovo's BTM has taken over 2 years to get VAC approved in some accounts too.
 
watchlist Created with Sketch. Add AVH (ASX) to my watchlist
(20min delay)
Last
$3.09
Change
0.130(4.39%)
Mkt cap ! $210.4M
Open High Low Value Volume
$3.10 $3.22 $3.08 $1.347M 431.2K

Buyers (Bids)

No. Vol. Price($)
1 5559 $3.09
 

Sellers (Offers)

Price($) Vol. No.
$3.10 687 1
View Market Depth
Last trade - 16.10pm 24/07/2024 (20 minute delay) ?
AVH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.